Sun Pharma Q4 FY25: Profit May Rise 18% YoY to ₹3,070 Cr

Sun Pharmaceutical Industries is set to announce its Q4 FY25 (Jan-Mar 2025 quarter) results on May 22, 2025. Ahead of the release, analystsexpect strong growth led by its speciality drugs and domestic portfolio. In Q4 FY25, consensus forecasts peg revenue at roughly ₹13,550 crore (≈13.6% YoY growth) and net profit around ₹3,070 crore. This implies earnings of about ₹14 per share, given Sun Pharma's share count. These estimates reflect double-digit sales gains from products like Ilumya and gRevlimid, offsetting some moderation in its US generics business.